Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

3 Takeaways From Amarin's Earnings

TheMotleyFool

0 0

Before the opening bell on Wednesday, Amarin (NASDAQ: AMRN) reported its second-quarter earnings, with the biopharma easily beating the consensus for both its top and bottom lines for the three-month period. In fact, the company reported a record-setting revenue haul of $100.8 million in the second quarter, fueled by surging sales of the prescription omega-3 treatment Vascepa.

While stronger-than-expected earnings are always a positive, Amarin's Q2 report arguably gave investors a lot more to chew on than just financial facts and figures. Here are three key takeaways from the biotech's upbeat earnings release.

Image source: Getty Images.

Quelle Fool.com

Like: 0

AMRN

Teilen